key: cord-0305235-c8yf2tel
authors: Blair, P. W.; Brandsma, J.; Chenoweth, J. G.; Richard, S. A.; Epsi, N. J.; Mehta, R.; Striegel, D. A.; Clemens, E. G.; Lindholm, D. A.; Maves, R. C.; Larson, D. T.; Mende, K.; Colombo, R. E.; Ganesan, A.; Lalani, T.; Colombo, C. J.; Malloy, A. A.; Snow, A. L.; Schully, K. L.; Lanteri, C.; Simons, M. P.; Dumler, J. S.; Tribble, D.; Burgess, T.; Pollett, S.; Agan, B. K.; Clark, D. V.; Group, EPICC COVID-19 Cohort Study
title: Topological data analysis identifies distinct biomarker phenotypes during the inflammatory phase of COVID-19
date: 2021-12-29
journal: nan
DOI: 10.1101/2021.12.25.21268206
sha: df818ed7d1760d12a3ce3d81915d32edf46c1d77
doc_id: 305235
cord_uid: c8yf2tel

OBJECTIVES: The relationships between baseline clinical phenotypes and the cytokine milieu of the peak inflammatory phase of coronavirus 2019 (COVID-19) are not yet well understood. We used Topological Data Analysis (TDA), a dimensionality reduction technique to identify patterns of inflammation associated with COVID-19 severity and clinical characteristics. DESIGN: Exploratory analysis from a multi-center prospective cohort study. SETTING: Eight military hospitals across the United States between April 2020 and January 2021. PATIENTS: Adult ([≥]18 years of age) SARS-CoV-2 positive inpatient and outpatient participants were enrolled with plasma samples selected from the putative inflammatory phase of COVID-19, defined as 15-28 days post symptom onset. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Concentrations of 12 inflammatory protein biomarkers were measured using a broad dynamic range immunoassay. TDA identified 3 distinct inflammatory protein expression clusters. Peak severity (outpatient, hospitalized, ICU admission or death), Charlson Comorbidity Index (CCI), and body mass index (BMI) were evaluated with logistic regression for associations with each cluster. The study population (n=129, 33.3% female, median 41.3 years of age) included 77 outpatient, 31 inpatient, 16 ICU-level, and 5 fatal cases. Three distinct clusters were found that differed by peak disease severity (p <0.001), age (p <0.001), BMI (p<0.001), and CCI (p=0.001). CONCLUSIONS: Exploratory clustering methods can stratify heterogeneous patient populations and identify distinct inflammation patterns associated with comorbid disease, obesity, and severe illness due to COVID-19.

While clinical risk factors for coronavirus disease 2019 (COVID-19) severity have been described, mechanisms of inflammation associated with these baseline clinical features are less understood (1). SARS-(2). However, the pathways from host factors to COVID-19 severity and sequelae are largely unknown.

during SARS-CoV-2 infection (4). Our analysis focused on samples collected during the inflammatory 115 phase from an observational cohort of participants with mild to severe COVID-19 at military treatment 116 facilities. Inflammatory biomarkers were selected from prior unpublished non-COVID-19 sepsis TDA 117 analyses (10) and from clinical use (11) . We sought to demonstrate that this analytical approach can help 118 discern inflammatory patterns to find possible treatment targets, as well as serve as a tool to understand These trends were consistent with the literature, and, accordingly, the TDA was restricted to the 129 baricitinib, tocilizumab, hydroxychloroquine, or systemic steroids (equivalent to prednisone 10mg daily or 143 above) at the time of blood collection was determined through the electronic medical record or participant 144 surveys.

Plasma samples were prospectively collected after enrollment as previously described (13). Venous whole 147 blood samples were centrifuged for 10 minutes at 1500 g and collected plasma was stored at −80°C. A 148 panel of 12 inflammatory proteins were measured in the plasma samples using the high dynamic range 149 automated enzyme-linked immunosorbent assay Ella microfluidic analyzer (ProteinSimple, San Jose,

California, USA). The panel included: IL-6, CXCL10, IL-1RA, D-dimer, procalcitonin, ferritin, VEGF-A, 151 IL-5, soluble receptor for advanced glycation end-product (RAGE), TNFR1, IFN-γ, and C-reactive protein 152 (CRP). This panel was selected to include analytes in clinical use for prognostication (i.e., CRP, 153 procalcitonin, ferritin, and D-dimer)(11), based on prior COVID-19 literature (i.e., IL-6, IFN-γ and 154 CXCL10) (15), and identified to be representative of prior TDA-based non-COVID-19 sepsis clusters (i.e.,

IL-1RA, VEGF-A, IL-5, RAGE, and TNFR1) (10, 16). All protein concentrations were log10-transformed 156 and normalized for site-to-site variation using the R package SVA ComBat (17). A small number (1.6%) of either the lowest or highest measured value within range of the Ella platform. Correlation between analytes 159 was explored with a principal component analysis and determining the Spearman's correlation coefficients.

For some subjects, multiple samples were available. In such cases, the sample with the highest coefficient 161 of variation across all analytes was retained to incorporate the largest degree of relative variability at that This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 algorithm using the EurekaAI platform (SymphonyAI, Los Altos, CA, USA) (7, 19, 20) . TDA networks 166 were generated for a range of resolution settings to examine the persistence of subject clusters and their 167 interrelatedness. Peaked severity (outpatient, hospitalized, ICU-level or death) color gradients were 168 overlaid on identified clusters. Levels of the individual proteins in each TDA group were summarized in a 169 series of boxplots (R package "ggplot2" v3.3.5). Backward selection stepwise logistic regression using a 170 Bernoulli-adjusted significance level of 0.0042 (i.e., 0.05/12) was used to identify which proteins were up-171 or downregulated within each cluster. While TDA clusters will inherently have different biomarker levels, This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10. 1101 /2021 EPICC cohort between 0-28 dpso using a scatter plot with LOESS (locally estimated scatterplot smoothing) Based on these findings and the inflammatory phase literature, we restricted our analysis to 129 participants 195 (66.7% male, median 41.3 years of age) including 77 outpatient, 31 inpatient, 16 ICU-level, and 5 fatal 196 cases (Table 1) 

Age differed significantly between TDA clusters (p<0.001). Participants from TDA Clusters 2 (median 204 37.1 years of age; IQR, 28.1 to 50.0) and 3 (median 36.3 years of age; IQR, 24.6 to 55.2) were younger 205 than in Cluster 1 (median 51.8 years of age; IQR, 37.3 to 65.0) ( Table 1 ). The prevalence of male gender 206 was similar among Cluster 1 (62.0%, n=31), Cluster 2 (64.1%, n=41), and the general cohort (66.7%), but 207 cluster 3 was predominantly male (93.3%, n=14). The median time from symptom onset to sample 208 collection was 21 days (IQR 18 to 25) and did not differ between clusters (Table 1) . Peak disease severity, 209 as categorized by hospitalization status, was also found to differ significantly among the TDA clusters Table S1 .). When restricting the analysis to those not receiving steroids, the models were 248 qualitatively unchanged, and the same covariates were selected.

We demonstrated that a multi-site prospective patient cohort can be stratified into three distinct 252 inflammatory profiles using 12 protein biomarkers from samples collected during the inflammatory phase 253 of COVID-19. TDA dimensionality reduction was able to identify biomarker patterns with differences in 254 both severity and comorbid conditions between cluster phenotypes. Combinations of biomarkers, 255 independent of clinical information, grouped participants into one of three distinct clusters: high COVID-256 19 severity, older, with comorbid conditions (Cluster 1); low severity, younger, less comorbid illness 257 (Cluster 2); and a moderate severity, younger, previously healthy, male-predominant group (Cluster 3).

This proof-of-concept study identifies potential use of TDA as a strategy to identify biomarker clusters This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Cluster 3 was unique in that it had a combination of low VEGF-A but had elevated ferritin and higher 277 prevalence of severe illness compared to Cluster 2, a mild illness cluster with comparable demographics.

While sample size is limited, 14 of 15 participants in Cluster 3 were male, suggestive of a biologic sex 279 difference in immune response among these previously healthy young men. Sex differences leading to 

In contrast to prior research (27), RAGE levels appeared to be higher among the younger and relatively 287 milder COVID-19 severity Cluster 2 compared to Cluster 1. Compared to other clusters, RAGE was 288 elevated along with IFN-γ in the less symptomatic Cluster 2, but with lower acute phase reactants ferritin 289 and procalcitonin. The converse was true with Cluster 1 where lower levels of RAGE in individuals were 290 noted, along with elevated acute phase reactants (i.e., CRP, procalcitonin, and ferritin). This association 291 of lower RAGE with higher severity Clusters 1 and 3 contrasts with a direct association with COVID-19 292 mortality (28). However, our results may differ by accounting for biomarker patterns rather than 293 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 evaluating each biomarker in isolation. It is possible that RAGE could be an indicator of severity during 294 certain disease states but functioning as an adaptive anti-inflammatory protein in Cluster 2 during the 295 inflammatory phase. Soluble RAGE has been shown to reduce vascular injury in rodent models (29, 30) 296 and could be protective against vascular inflammation mediated the RAGE receptor (31). The This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to this version posted December 29, 20 ; This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. *Distributions among all clusters compared using a Kruskal-Wallis test.

for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 29, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

Systemic Inflammation and COVID-19 Mortality in

Topological methods for the analysis of high dimensional data

Topological data analysis reveals genotype-phenotype 18

Extracting insights from the shape of complex data using 30

RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes

Vascular and inflammatory stresses mediate atherosclerosis